Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) Research & Development (2018 - 2025)

Exagen (XGN) has disclosed Research & Development for 8 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 6.1% year-over-year to $1.8 million, compared with a TTM value of $6.3 million through Dec 2025, up 16.35%, and an annual FY2025 reading of $6.3 million, up 16.35% over the prior year.
  • Research & Development was $1.8 million for Q4 2025 at Exagen, up from $1.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $2.7 million in Q4 2022 and bottomed at $1.1 million in Q1 2024.
  • Average Research & Development over 5 years is $1.7 million, with a median of $1.6 million recorded in 2024.
  • The sharpest move saw Research & Development surged 151.93% in 2021, then tumbled 60.16% in 2023.
  • Year by year, Research & Development stood at $2.2 million in 2021, then grew by 22.66% to $2.7 million in 2022, then tumbled by 60.16% to $1.1 million in 2023, then surged by 53.9% to $1.7 million in 2024, then rose by 6.1% to $1.8 million in 2025.
  • Business Quant data shows Research & Development for XGN at $1.8 million in Q4 2025, $1.7 million in Q3 2025, and $1.5 million in Q2 2025.